Plasma levels of total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride, Apo A-1, and Apo B in patients with Stroke in Ogbomoso, Southwestern Nigeria
Journal of Applied Biology & Biotechnology
Hyperlipidemia is a strong factor in the development of stroke, but this may differ from one region to another due to geographic, ethnic, and sociocultural practices. This is designed to determine plasma levels of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, Apoprotein A-1, and Apoprotein B in Nigerian patients with stroke. 50 newly diagnosed stroke patients were consecutively recruited into the study. 50 apparently
... 50 apparently healthy, age-and sex-matched volunteers were recruited from Ogbomoso community as controls. The data obtained were analyzed using the Statistical Package for the Social Sciences (SPSS) version 20. Higher and lower significant levels (P < 0.001), respectively, were observed in the plasma total cholesterol (4.5 ± 1.41 vs. 3.90 ± 0.91 mmol/l), LDL-cholesterol (3.32 ± 1.41 vs. 2.19 ± 0.82 mmol/l), HDL-cholesterol (0.76 ± 0.32 vs. 1.27 ± 0.38 mmol/l), and Apo A1 (0.87 ± 0.73 vs. 4.56 ± 2.40) in stroke patients when compared with controls. There was a lower significant difference in plasma level of Apo A1 in patients with ischemic stroke (0.734 ± 0.64 vs. 1.31 ± 0.84) when compared with hemorrhagic stroke (P < 0.005). The mean plasma level of Apo B (1.70 ± 1.05 vs. 1.09 ± 0.40) in ischemic stroke was higher than patients with hemorrhagic stroke, though difference was not statistically significant (P ≥ 0.005). We concluded that apoproteins remain the significant biochemical markers that may be deranged in patients with stroke. There are associations between Apo A1 and Apo B. It is encouraged that plasma apoproteins estimation should be added to routine investigations done on stroke patients in this environment.